SCHEMBL30510390

SCHEMBL30510390

COC(=O)N(C1c2ccccc2-c2ccccc21)[C@@H](CC1CCC1)C(=O)O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPY5R Q15761 1/20 0.36
▸ BCHE P06276 1/20 0.35
▸ ACHE P22303 1/20 0.35
▸ METAP2 P50579 1/20 0.35
▸ METAP1 P53582 1/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNB4 P30926 1/20 0.35
▸ CHRNA3 P32297 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ MME P08473 1/20 0.34
▸ ACE P12821 1/20 0.34
▸ CPA1 P15085 1/20 0.34
▸ ACE2 Q9BYF1 1/20 0.34
▸ AGTR1 P30556 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ SLC6A2 P23975 1/20 0.34
▸ SLC6A4 P31645 1/20 0.34
▸ SLC6A3 Q01959 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25173094 1.00 NPY5R (0.36) NPY5RBCHEACHEMETAP2METAP1
SCHEMBL25179536 0.98 NPY5R (0.39) NPY5RBCHEACHEMETAP2METAP1
SCHEMBL30510422 0.98 NPY5R (0.39) NPY5RBCHEACHEMETAP2METAP1
SCHEMBL5409646 0.97 NPY5R (0.40) NPY5RMETAP2METAP1MMEACE
SCHEMBL30510220 0.97 NPY5R (0.40) NPY5RMETAP2METAP1MMEACE
SCHEMBL25178677 0.95 CYP1A2 (0.35) NPY5RCYP1A2TSHRCYP2D6SLC6A2
SCHEMBL30510378 0.95 CYP1A2 (0.35) NPY5RCYP1A2TSHRCYP2D6SLC6A2
SCHEMBL7718775 0.88 CHRNB2 (0.42) CHRNB2CHRNB4CHRNA3CHRNA4CYP2D6
SCHEMBL30054811 0.84 ALDH1A1 (0.35) CYP1A2TSHRCYP2D6SLC6A2SLC6A4
SCHEMBL25177898 0.83 CYP1A2 (0.37) CYP1A2TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-07-29 — — US disclosed
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-12-05 — — US disclosed
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2023-05-18 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230151060-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS NPY5R 3618/4885BCHE 3116/4885ACHE 4434/4885
US-20240400617-A1 CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION KRAS, NRAS, HRAS NPY5R 3618/4885BCHE 3116/4885ACHE 4434/4885
US-12371454-B2 Cyclic peptide compound having Kras inhibitory action KRAS, NRAS, HRAS NPY5R 3618/4885BCHE 3116/4885ACHE 4434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback